WP
AST

WealthPLAN Partners’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

WealthPLAN Partners’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$289 Sell
70
-70
-50% -$226 ﹤0.01% 933
2016
Q2 		$168 Buy
+140
New +$506 ﹤0.01% 2413
2015
Q4 		$114 Buy
+87
New +$401 ﹤0.01% 1635
2015
Q2 		$0 Hold
29
– – ﹤0.01% 567
2015
Q1 		$0 Buy
+29
New +$144 ﹤0.01% 561

Other funds holding AST

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

WealthPLAN Partners's AST Position: Q3 2016 in Review

WealthPLAN Partners reduced its Asterias Biotherapeutics Inc. Series A (AST) stake by 50% in Q3 2016, selling an estimated $226 and leaving 70 shares worth $289. The position accounts for ﹤0.01% of the portfolio, ranked #933.

WealthPLAN Partners first reported a position in AST in Q1 2015 and has held it in 5 quarters since. 64 funds tracked by Wall St. Rank hold AST as of Q3 2016.

  • WealthPLAN Partners held 70 shares of Asterias Biotherapeutics Inc. Series A worth $289 as of Q3 2016.
  • WealthPLAN Partners sold 70 Asterias Biotherapeutics Inc. Series A shares in Q3 2016, an estimated $226.
  • Asterias Biotherapeutics Inc. Series A made up ﹤0.01% of WealthPLAN Partners's portfolio in Q3 2016, its #933 holding.
  • WealthPLAN Partners first reported a position in Asterias Biotherapeutics Inc. Series A in Q1 2015 and has held it in 5 quarters since.
  • 64 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q3 2016.

Based on WealthPLAN Partners's 13F filing for Q3 2016, filed 9 Dec 2016.